Exact Mass: 362.19876600000003
Exact Mass Matches: 362.19876600000003
Found 92 metabolites which its exact mass value is equals to given mass value 362.19876600000003,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
17,21-Epoxy-9-fluoro-11beta-hydroxyprogesterone
N-(4-Fluorophenyl)-4,5-dimethyl-6-[(1S)-1-methyl-3,4-dihydro-1H-isoquinolin-2-YL]pyrimidin-2-amine
C22H23FN4 (362.19066499999997)
C78276 - Agent Affecting Digestive System or Metabolism > C29701 - Anti-ulcer Agent
Benzetimide
D002491 - Central Nervous System Agents > D018726 - Anti-Dyskinesia Agents > D000978 - Antiparkinson Agents C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D010276 - Parasympatholytics D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D018680 - Cholinergic Antagonists
9R-(beta-D-glucopyranosyloxy)-cis-cascarillic acid|parisveroside A
(±)-JWH 018 N-(4-hydroxypentyl) metabolite-d5
C24H18D5NO2 (362.20425568999997)
JWH 018 N-(5-hydroxypentyl) metabolite-d5
C24H18D5NO2 (362.20425568999997)
(4R,4R)-2,2-(PROPANE-2,2-DIYL)BIS(4-BENZYL-4,5-DIHYDROOXAZOLE)
solifenacin
G - Genito urinary system and sex hormones > G04 - Urologicals > G04B - Urologicals > G04BD - Drugs for urinary frequency and incontinence C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D018680 - Cholinergic Antagonists D000089162 - Genitourinary Agents > D064804 - Urological Agents Solifenacin (YM905 free base) is a novel muscarinic receptor antagonist with pKis of 7.6, 6.9 and 8.0 for M1, M2 and M3 receptors, respectively.
N,N-bis(2-aminoethyl)ethane-1,2-diamine,2-(chloromethyl)oxirane,formaldehyde,phenol
N-(2-((tert-Butyldimethylsilyloxy)methyl)furo[3,2-b]pyridin-7-yl)pivalamide
sodium n-tridecylbenzenesulfonate
C19H31NaO3S (362.18914960000006)
4,4-DIISOCYANATO-3,3,5,5-TETRAETHYLDIPHENYLMETHANE
Dexetimide
D002491 - Central Nervous System Agents > D018726 - Anti-Dyskinesia Agents > D000978 - Antiparkinson Agents N - Nervous system > N04 - Anti-parkinson drugs > N04A - Anticholinergic agents > N04AA - Tertiary amines C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D010276 - Parasympatholytics D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D018680 - Cholinergic Antagonists Dexetimide ((+)-Benzetimide; (S)-(+)-Dexetimide; Dexbenzetimide) is a piperidine anticholinergic and a high-affinity muscarinic receptor antagonist. Dexetimide can be used in studies of parkinson's disease[1][2].
EPOXYPROPOXYPROPYL TERMINATED POLYDIMETHYLSILOXANE
2,8-Diazaspiro[5.5]undecane-1,7-dione, 2,8-bis(phenylmethyl)-
1-[4-[1-(3-methoxy-4-nitrophenyl)piperidin-4-yl]piperazin-1-yl]ethanone
C18H26N4O4 (362.19539560000004)
Clometherone
C274 - Antineoplastic Agent > C129818 - Antineoplastic Hormonal/Endocrine Agent > C481 - Antiestrogen C147908 - Hormone Therapy Agent > C547 - Hormone Antagonist
(6S)-6-Cyclopentyl-6-[2-(3-fluoro-4-isopropoxyphenyl)ethyl]-4-hydroxy-5,6-dihydro-2H-pyran-2-one
benzetimide
D002491 - Central Nervous System Agents > D018726 - Anti-Dyskinesia Agents > D000978 - Antiparkinson Agents C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D010276 - Parasympatholytics D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D018680 - Cholinergic Antagonists
5-(Phenylmethoxymethyl)-7-(1-piperidinylmethyl)-8-quinolinol
(4S)-4-phenyl-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid [(3R)-1-azabicyclo[2.2.2]octan-3-yl] ester
17,21-Epoxy-9-fluoro-11-hydroxypregn-4-ene-3,20-dione, (11beta)-
N(6)-L-homocysteinyl-N(2)-L-valyl-L-lysine
C15H30N4O4S (362.19876600000003)
1-[(4-Chlorophenyl)-[1-(2-methylbutan-2-yl)-5-tetrazolyl]methyl]-4-methylpiperazine
N-[2-[(2R,5S,6R)-5-[[cyclobutyl(oxo)methyl]amino]-6-(hydroxymethyl)-2-oxanyl]ethyl]-2-pyrazinecarboxamide
C18H26N4O4 (362.19539560000004)
N-[2-[(2R,5R,6S)-5-[[cyclobutyl(oxo)methyl]amino]-6-(hydroxymethyl)-2-oxanyl]ethyl]-2-pyrazinecarboxamide
C18H26N4O4 (362.19539560000004)
N-[2-[(2S,5S,6S)-5-[[cyclobutyl(oxo)methyl]amino]-6-(hydroxymethyl)-2-oxanyl]ethyl]-2-pyrazinecarboxamide
C18H26N4O4 (362.19539560000004)
1-[(3aR,4R,9bR)-4-(hydroxymethyl)-8-phenyl-2,3,3a,4,5,9b-hexahydropyrrolo[3,2-c]quinolin-1-yl]-2-cyclopropylethanone
(6S,7S,8R)-4-benzyl-8-(hydroxymethyl)-7-[4-[(E)-prop-1-enyl]phenyl]-1,4-diazabicyclo[4.2.0]octan-2-one
N-[2-[(2S,5R,6S)-5-[[cyclobutyl(oxo)methyl]amino]-6-(hydroxymethyl)-2-oxanyl]ethyl]-2-pyrazinecarboxamide
C18H26N4O4 (362.19539560000004)
N-[2-[(2R,5R,6R)-5-[[cyclobutyl(oxo)methyl]amino]-6-(hydroxymethyl)-2-oxanyl]ethyl]-2-pyrazinecarboxamide
C18H26N4O4 (362.19539560000004)
N-[2-[(2R,5S,6S)-5-[[cyclobutyl(oxo)methyl]amino]-6-(hydroxymethyl)-2-oxanyl]ethyl]-2-pyrazinecarboxamide
C18H26N4O4 (362.19539560000004)
N-[2-[(2S,5S,6R)-5-[[cyclobutyl(oxo)methyl]amino]-6-(hydroxymethyl)-2-oxanyl]ethyl]-2-pyrazinecarboxamide
C18H26N4O4 (362.19539560000004)
N-[2-[(2S,5R,6R)-5-[[cyclobutyl(oxo)methyl]amino]-6-(hydroxymethyl)-2-oxanyl]ethyl]-2-pyrazinecarboxamide
C18H26N4O4 (362.19539560000004)
1-[(3aS,4R,9bS)-4-(hydroxymethyl)-8-phenyl-2,3,3a,4,5,9b-hexahydropyrrolo[3,2-c]quinolin-1-yl]-2-cyclopropylethanone
1-[(3aS,4S,9bS)-4-(hydroxymethyl)-8-phenyl-2,3,3a,4,5,9b-hexahydropyrrolo[3,2-c]quinolin-1-yl]-2-cyclopropylethanone
1-[(3aR,4S,9bR)-4-(hydroxymethyl)-8-phenyl-2,3,3a,4,5,9b-hexahydropyrrolo[3,2-c]quinolin-1-yl]-2-cyclopropylethanone
(6R,7S,8R)-4-benzyl-8-(hydroxymethyl)-7-[4-[(E)-prop-1-enyl]phenyl]-1,4-diazabicyclo[4.2.0]octan-2-one
revaprazan
C22H23FN4 (362.19066499999997)
C78276 - Agent Affecting Digestive System or Metabolism > C29701 - Anti-ulcer Agent
Levetimide
Levetimide is a potent and stereoselective inhibitor of [3H](+)pentazocine binding, with a Ki of 2.2 nM[1].
(2E,6E)- 3,7,11-trimethyl-9-(phenylsulfonyl)-2,6,10-dodecatrien-1-ol
{"Ingredient_id": "HBIN005569","Ingredient_name": "(2E,6E)- 3,7,11-trimethyl-9-(phenylsulfonyl)-2,6,10-dodecatrien-1-ol","Alias": "NA","Ingredient_formula": "C21H30O3S","Ingredient_Smile": "CC(=CC(CC(=CCCC(=CCO)C)C)S(=O)(=O)C1=CC=CC=C1)C","Ingredient_weight": "362.5 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "41632","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "5368759","DrugBank_id": "NA"}